[{"orgOrder":0,"company":"Senisca","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"SENISCA Awarded Innovate UK Grant to Develop Oligonucleotide Therapeutics for The Treatment of Idiopathic Pulmonary Fibrosis (IPF).","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Senisca","sponsor":"Emerging Longevity Ventures","pharmaFlowCategory":"D","amount":"$4.7 million","upfrontCash":"Undisclosed","newsHeadline":"Senisca Secures Additional \u00a33.7 Million Financing to Support Rapid Development of Senotherapeutic Platform to Treat Age-Related Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Senisca
The net proceeds will support the preclinical development of the Company’s senotherapeutic programmes, that target the causes of age-related disease via RNA splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence.
The funding will be used towards the development of Oligonucleotide-based Thearpies for the treatment of idiopathic pulmonary fibrosis (IPF), using SENISCA’s proprietary technology, harnessing RNA biology to rejuvenate aged senescent cells.